MedTrace Logo

A Study to Assess the Effect of Rifampin on the Metabolism of ABT-199

NCT01969682 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2014-05-26

No results posted yet for this study

Summary

This is an open-label multicenter, study to assess the pharmacokinetic interaction of rifampin with ABT-199 in up to 12 subjects with relapsed or refractory non-Hodgkin's lymphoma.

Conditions

  • Non-Hodgkin's Lymphoma

Interventions

DRUG

ABT-199

Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin

DRUG

Rifampin

Subjects will be dosed with ABT-199, then dosed with ABT-199 in combination with rifampin

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • AbbVie

    lead INDUSTRY

Principal Investigators

  • David Chien, MD · AbbVie

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-04-30
Primary Completion
2014-05-31
Completion
2014-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01969682 on ClinicalTrials.gov